

# Our Evolving Growth Story

Industry-leading performance positioned us for continued growth into 2019, as we launch new therapies for patients.



## Delivering on our Commitments

Since 2013, we have consistently demonstrated our ability to deliver on our commitments, and 2018 was no exception. Our strong financial performance supports the complex research required to meet today's health challenges, while delivering an industry-leading investment return to shareholders.


For a complete look at our 2018 performance, our earnings press release is located [here](#).

## Compelling Pipeline

Our pipeline was built for long-term growth, with programs chosen for their potential to advance the treatment landscape and provide innovative medicines to patients. We are entering a new phase of our evolution where the strength of the pipeline will be clearly demonstrated as a large number of our medicines become available. Learn more about our pipeline [here](#).

## Total Product or Indication Approvals Since 2013

Therapeutic Focus Area:




Science and innovation are the cornerstones of our business, and we continue to make significant, strategic investments in R&D to advance our pipeline. Learn more about the transformative science AbbVie is supporting that could change the landscape of some of the world's most complex diseases [here](#).

## Annual R&D Investment (adjusted)



\*2013 GAAP R&D investment of \$2.9B, 2018 GAAP R&D investment of \$10.3B.

The combination of our innovation and commercial execution has resulted in a portfolio of new and differentiated medicines that benefit millions of patients across a large and growing number of therapeutic areas. In 2018, almost a quarter of our revenue came from products launched since separation.



## Creating Shareholder Value

Our strong execution has produced exceptional and industry-leading shareholder value, delivering total shareholder returns of 235%\* since 2013.



\* As of December 31, 2018

A strong dividend is an important part of our investment identity, and we have grown our quarterly dividend significantly since inception.



\* Dividend of \$1.07 per share beginning with the dividend payable on February 15, 2019.

## Achieving Continued Success

Since 2013, we have built a strong foundation as a patient-focused and high performing company. For us, the future is always present, filled with the potential for advancing science and patient care. We remain focused on discovering and delivering medicines where we have proven expertise, while operating responsibly and positively impacting the communities where we live and work.

For Investor and Media Use Only - Not For Promotional Use